Key result
Primary pulmonary hypertension and cor pulmonale present with right ventricular dysfunction and are managed with therapies including supplemental oxygen, anticoagulation, prostacyclin, and bosentan.
This review summarizes the pathophysiology, clinical presentation, and therapeutic options for primary pulmonary hypertension and cor pulmonale, highlighting prostacyclin and bosentan as key treatments.
May inform management of primary pulmonary hypertension; leaves open need for updated randomized trials.
Primary pulmonary hypertension and cor pulmonale represent forms of precapillary pulmonary hypertension due to intrinsic lung disease. In the case of primary pulmonary hypertension, this is due to disease of the pulmonary vasculature while cor pulmonale is related to diseases of the pulmonary vasculature, airways, or interstitium. Patients present with signs and symptoms of right ventricular dysfunction and low cardiac output including dyspnea, chest pain and peripheral edema. Therapy is directed at the underlying disease and may include supplemental oxygen for diseases causing chronic hypoxemia and anticoagulation for thrombotic disease. Vasodilator therapy has variable efficacy for pulmonary vascular disorders. Postacyclin by continuous infusion has been a major advance in the therapy of primary pulmonary hypertension and has prolonged survival and delayed the need for lung transplantation. Bosentan, an endothelin receptor blocking agent is the first oral medication approved for the therapy of pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Lehrman et al. (2002) conducted a review in Primary pulmonary hypertension and cor pulmonale. Primary pulmonary hypertension and cor pulmonale present with right ventricular dysfunction and are managed with therapies including supplemental oxygen, anticoagulation, prostacyclin, and bosentan.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: